In vitro-induced antibody production in chronic hepatitis C virus infection

Detalhes bibliográficos
Autor(a) principal: Oliveira Jr.,E.B.
Data de Publicação: 2003
Outros Autores: Ferraz,M.L.G., Perez,R.M., Silva,A.E.B., Lanzoni,V.P., Granato,C.F.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300011
Resumo: The objectives of the present study were to assess the in vitro-induced anti-hepatitis C virus (HCV) antibody production (IVIAP) in relation to the clinical, biochemical, virologic and histologic variables of patients with HCV infection. The study included 57 patients (60% males) with HCV infection (anti-HCV and HCV-RNA positive). Alanine aminotransferase (ALT) was elevated in 89% of the patients. Mean viral load was 542,241 copies/ml and histology of the liver showed chronic hepatitis in 27/52 (52%) and cirrhosis in 11/52 (21%) patients. IVIAP levels were determined by immunoenzymatic assay at median absorbance of 0.781 at 450 nm. IVIAP was negative in 14% of the patients. When groups with IVIAP levels above and below the median were compared, high IVIAP levels were associated with the male sex, elevated ALT levels and more advanced disease stage. After logistic regression analysis, advanced histologic damage to the liver remained as the only independent variable associated with elevated IVIAP levels. Using a receiver operator characteristic curve, the best cut-off level for IVIAP was established (= 1.540), with 71% sensitivity and 94% specificity for the detection of more advanced disease stages (grades 3 and 4). These findings are consistent with the participation of immunological mechanisms in the genesis of the hepatic lesions induced by HCV and indicate that the IVIAP test may be useful as a noninvasive marker of liver damage either alone or in combination with other markers.
id ABDC-1_c5372972f1dcf5b3eda376f658a3cfb4
oai_identifier_str oai:scielo:S0100-879X2003000300011
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling In vitro-induced antibody production in chronic hepatitis C virus infectionHepatitis CIn vitro-induced antibody productionIVIAPHepatitis C virus-RNALiver biopsyAnti-HCV antibodiesThe objectives of the present study were to assess the in vitro-induced anti-hepatitis C virus (HCV) antibody production (IVIAP) in relation to the clinical, biochemical, virologic and histologic variables of patients with HCV infection. The study included 57 patients (60% males) with HCV infection (anti-HCV and HCV-RNA positive). Alanine aminotransferase (ALT) was elevated in 89% of the patients. Mean viral load was 542,241 copies/ml and histology of the liver showed chronic hepatitis in 27/52 (52%) and cirrhosis in 11/52 (21%) patients. IVIAP levels were determined by immunoenzymatic assay at median absorbance of 0.781 at 450 nm. IVIAP was negative in 14% of the patients. When groups with IVIAP levels above and below the median were compared, high IVIAP levels were associated with the male sex, elevated ALT levels and more advanced disease stage. After logistic regression analysis, advanced histologic damage to the liver remained as the only independent variable associated with elevated IVIAP levels. Using a receiver operator characteristic curve, the best cut-off level for IVIAP was established (= 1.540), with 71% sensitivity and 94% specificity for the detection of more advanced disease stages (grades 3 and 4). These findings are consistent with the participation of immunological mechanisms in the genesis of the hepatic lesions induced by HCV and indicate that the IVIAP test may be useful as a noninvasive marker of liver damage either alone or in combination with other markers.Associação Brasileira de Divulgação Científica2003-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300011Brazilian Journal of Medical and Biological Research v.36 n.3 2003reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2003000300011info:eu-repo/semantics/openAccessOliveira Jr.,E.B.Ferraz,M.L.G.Perez,R.M.Silva,A.E.B.Lanzoni,V.P.Granato,C.F.eng2003-03-07T00:00:00Zoai:scielo:S0100-879X2003000300011Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2003-03-07T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv In vitro-induced antibody production in chronic hepatitis C virus infection
title In vitro-induced antibody production in chronic hepatitis C virus infection
spellingShingle In vitro-induced antibody production in chronic hepatitis C virus infection
Oliveira Jr.,E.B.
Hepatitis C
In vitro-induced antibody production
IVIAP
Hepatitis C virus-RNA
Liver biopsy
Anti-HCV antibodies
title_short In vitro-induced antibody production in chronic hepatitis C virus infection
title_full In vitro-induced antibody production in chronic hepatitis C virus infection
title_fullStr In vitro-induced antibody production in chronic hepatitis C virus infection
title_full_unstemmed In vitro-induced antibody production in chronic hepatitis C virus infection
title_sort In vitro-induced antibody production in chronic hepatitis C virus infection
author Oliveira Jr.,E.B.
author_facet Oliveira Jr.,E.B.
Ferraz,M.L.G.
Perez,R.M.
Silva,A.E.B.
Lanzoni,V.P.
Granato,C.F.
author_role author
author2 Ferraz,M.L.G.
Perez,R.M.
Silva,A.E.B.
Lanzoni,V.P.
Granato,C.F.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira Jr.,E.B.
Ferraz,M.L.G.
Perez,R.M.
Silva,A.E.B.
Lanzoni,V.P.
Granato,C.F.
dc.subject.por.fl_str_mv Hepatitis C
In vitro-induced antibody production
IVIAP
Hepatitis C virus-RNA
Liver biopsy
Anti-HCV antibodies
topic Hepatitis C
In vitro-induced antibody production
IVIAP
Hepatitis C virus-RNA
Liver biopsy
Anti-HCV antibodies
description The objectives of the present study were to assess the in vitro-induced anti-hepatitis C virus (HCV) antibody production (IVIAP) in relation to the clinical, biochemical, virologic and histologic variables of patients with HCV infection. The study included 57 patients (60% males) with HCV infection (anti-HCV and HCV-RNA positive). Alanine aminotransferase (ALT) was elevated in 89% of the patients. Mean viral load was 542,241 copies/ml and histology of the liver showed chronic hepatitis in 27/52 (52%) and cirrhosis in 11/52 (21%) patients. IVIAP levels were determined by immunoenzymatic assay at median absorbance of 0.781 at 450 nm. IVIAP was negative in 14% of the patients. When groups with IVIAP levels above and below the median were compared, high IVIAP levels were associated with the male sex, elevated ALT levels and more advanced disease stage. After logistic regression analysis, advanced histologic damage to the liver remained as the only independent variable associated with elevated IVIAP levels. Using a receiver operator characteristic curve, the best cut-off level for IVIAP was established (= 1.540), with 71% sensitivity and 94% specificity for the detection of more advanced disease stages (grades 3 and 4). These findings are consistent with the participation of immunological mechanisms in the genesis of the hepatic lesions induced by HCV and indicate that the IVIAP test may be useful as a noninvasive marker of liver damage either alone or in combination with other markers.
publishDate 2003
dc.date.none.fl_str_mv 2003-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X2003000300011
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.36 n.3 2003
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302932119977984